Subcutaneous Botulinum Toxin for Cutaneous Allodynia
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has
also been reported to be helpful for some pain conditions. The investigators have observed
prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin
Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to
study if addition of BTA extends pain relief compared to placebo when injected subcutaneously
into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is
perceived as painful).
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA